Vitaccess announces first-of-its-kind CIDP Registry and first patient enrolled in landmark patient-centered evidence platform
Boston, MA, USA and London, UK – 8 April 2026, Vitaccess, a leader in generating science-driven real-world evidence, announces the launch of the Vitaccess Real CIDP Registry, a first-of-its-kind patient-centered registry in chronic inflammatory demyelinating...
Vitaccess and Myasthenia Gravis Foundation of America form strategic partnership to advance generation of real-world evidence in MG
Boston, MA, USA and Oxford, UK – 12 February 2026. Vitaccess, a leader in generating science-driven real-world evidence, has entered into an exclusive partnership with the Myasthenia Gravis Foundation of America (MGFA), making the MGFA the official collaborator for...
MyRealWorld MG study announcement
The MyRealWorld MG study, a longitudinal digital observational study exploring the impact of myasthenia gravis (MG) from the patient perspective, has been run by Vitaccess on behalf of argenx since December 2019. Since then, over 2,400 adults with MG residing across...
American Health Research study launch
We are delighted to announce that this month, American Health Research, in collaboration with Vitaccess, have launched the investigator-initiated AHR CB study. The study is designed to help researchers learn how Mucinex® could be used as a long-term treatment to...
